Key facts
- Eurus Therapeutics’s last known valuation is $11.5M (Jun 2025).
- It has raised $7.2M; the latest was Early Stage VC ($5.6M) in Jun 2025.
- Notable investors include SMBC Venture Capital, Nissay Capital, Kyoto University Innovation Capital, Kyoto Capital Partners (Japan), Axil Capital Partners — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Eurus Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Eurus Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eurus Therapeutics
Developer of a novel genome editing technology designed to offer advancements in the medical industry. The company develops a new gene therapy with therapeutic strategies that can induce simple and precise genome editing without the use of exogenous proteins such as Cas, enabling the healthcare sector to solve the problems faced by the CRISPR/Cas system.
- Sector
- Healthcare
- HQ
- Fujisawa, Japan
- Founded
- 2021
- Ownership
- Privately Held (backing)
Eurus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eurus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eurus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.